JP2011522835A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522835A5
JP2011522835A5 JP2011512705A JP2011512705A JP2011522835A5 JP 2011522835 A5 JP2011522835 A5 JP 2011522835A5 JP 2011512705 A JP2011512705 A JP 2011512705A JP 2011512705 A JP2011512705 A JP 2011512705A JP 2011522835 A5 JP2011522835 A5 JP 2011522835A5
Authority
JP
Japan
Prior art keywords
cells
suppressor
antibody
isolated
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011512705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/046464 external-priority patent/WO2009149382A2/en
Publication of JP2011522835A publication Critical patent/JP2011522835A/ja
Publication of JP2011522835A5 publication Critical patent/JP2011522835A5/ja
Pending legal-status Critical Current

Links

JP2011512705A 2008-06-06 2009-06-05 抗cd8抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性cd8+t細胞の生成を導く Pending JP2011522835A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5964708P 2008-06-06 2008-06-06
US61/059,647 2008-06-06
PCT/US2009/046464 WO2009149382A2 (en) 2008-06-06 2009-06-05 Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells

Publications (2)

Publication Number Publication Date
JP2011522835A JP2011522835A (ja) 2011-08-04
JP2011522835A5 true JP2011522835A5 (cg-RX-API-DMAC7.html) 2012-07-19

Family

ID=41398905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512705A Pending JP2011522835A (ja) 2008-06-06 2009-06-05 抗cd8抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性cd8+t細胞の生成を導く

Country Status (14)

Country Link
US (1) US20090304659A1 (cg-RX-API-DMAC7.html)
EP (1) EP2297204A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011522835A (cg-RX-API-DMAC7.html)
KR (1) KR20110025812A (cg-RX-API-DMAC7.html)
CN (1) CN102112491A (cg-RX-API-DMAC7.html)
AU (1) AU2009255999A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0915582A2 (cg-RX-API-DMAC7.html)
CA (1) CA2728772A1 (cg-RX-API-DMAC7.html)
IL (1) IL209798A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010013265A (cg-RX-API-DMAC7.html)
NZ (1) NZ590197A (cg-RX-API-DMAC7.html)
TW (1) TW201000130A (cg-RX-API-DMAC7.html)
WO (1) WO2009149382A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100061B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5825966B2 (ja) * 2011-10-11 2015-12-02 株式会社日本バイオセラピー研究所 Cd56陽性t細胞増強方法
US10092597B2 (en) 2014-01-14 2018-10-09 The University Of Hong Kong Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice
WO2018085897A1 (en) * 2016-11-14 2018-05-17 Murdoch Childrens Research Institute Transplant rejection assay
MY197688A (en) * 2017-07-24 2023-07-05 Regeneron Pharma Anti-cd8 antibodies and uses thereof
JP7684656B2 (ja) 2019-06-11 2025-05-28 小野薬品工業株式会社 免疫抑制剤
US20240209089A1 (en) * 2020-07-21 2024-06-27 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. Cd8 binding polypeptide and use thereof
CN112156110B (zh) * 2020-09-15 2022-10-14 上海交通大学医学院 Cd8+抑制性t细胞在免疫调节中的应用及诱导方法
GB2638094A (en) 2021-05-19 2025-08-13 Asher Biotherapeutics Inc Il-21 Polypeptides And Targeted Constructs
CN120569191A (zh) 2022-11-23 2025-08-29 乔治亚大学研究基金公司 用于增加免疫应答的组合物及其使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178858A (en) * 1987-12-02 1993-01-12 Reichert Thomas A Method for prevention of graft versus host disease
CA1339840C (en) * 1988-12-16 1998-04-28 Kenneth Kortright Method and apparatus for screening cells or formed bodies with populations expressing selected characteristics
US5601828A (en) * 1989-03-15 1997-02-11 Tkb Associates Limited Partnership CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
ATE195550T1 (de) * 1990-11-23 2000-09-15 Coulter Corp Verfahren und vorrichtung zur reihensichtung mikroskopischer zellen unter verwendung von lichtstreuenden techniken
US6911220B1 (en) * 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
CA2250164C (en) * 1996-04-05 2011-12-06 South Alabama Medical Science Foundation Oncofetal antigen specific t-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific cd4, cd8 cytotoxic and suppressor t cells and interleukin-10
CA2252790A1 (en) * 1997-02-28 1998-09-03 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (sidr)
US6803036B1 (en) * 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
US20040022761A1 (en) * 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
JP4344696B2 (ja) * 2002-09-27 2009-10-14 バイオイー, インコーポレイテッド 細胞分離組成物および細胞分離法
EP1606313A2 (en) * 2003-03-19 2005-12-21 Isogenis, Inc. Specific inhibition of allograft rejection
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
JP2009542714A (ja) * 2006-06-30 2009-12-03 ベイラー リサーチ インスティテュート GM−CSF及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Similar Documents

Publication Publication Date Title
JP2011522835A5 (cg-RX-API-DMAC7.html)
JP7267976B2 (ja) 末梢免疫機能を調節するための方法及び組成物
Wang et al. Regulatory innate lymphoid cells control innate intestinal inflammation
EP3626817B1 (en) Methods of preparing anti-human papillomavirus antigen t cells
AU2006249640B2 (en) Dendritic cell compositions and methods
Yang et al. Interleukin-35 dampens CD8+ T cells activity in patients with non-viral hepatitis-related hepatocellular carcinoma
Ni et al. Clinical and basic research progress on Treg-induced immune tolerance in liver transplantation
TW200916581A (en) Paracrine signals from mesenchymal feeder cells and regulating expansion and differentiation of hepatic progenitors using same
Roberts et al. TNF blockade maintains an IL-10+ phenotype in human effector CD4+ and CD8+ T cells
de Haar et al. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation
CN101514333B (zh) 一种免疫耐受型树突状细胞及其制备方法与专用培养基
CN110607276A (zh) 高效扩增脐带血nk细胞的无血清培养方法
Kolanowski et al. Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-γ–matured type I dendritic cells for immunotherapy
De Felice et al. Hematopoietic, mesenchymal, and immune cells are more enhanced in bone marrow than in peripheral blood from granulocyte colony-stimulating factor primed healthy donors
Gel’m et al. Functional activity of lymphocytes of healthy donors and cancer patients after culturing with IL-2 and IL-15
CN108251370A (zh) 非细胞来源的多肽致敏的dc-cik细胞、其构建方法及应用
Li et al. The regulatory role of dendritic cells in the immune tolerance
CN113444688B (zh) 用于抗病毒抗肿瘤的人树突状细胞诱导方法及组合物
CN105219727A (zh) 一种用于激活结直肠癌特异性免疫反应的试剂盒
Naito et al. Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity
Hildenbrand et al. IFN-γ enhances Th1 polarisation of monocyte-derived dendritic cells matured with clinical-grade cytokines using serum-free conditions
CN102847145A (zh) 一种树突状细胞疫苗制备方法
CN114350608B (zh) 一种诱导t细胞重编程为类nk细胞的组合物及其应用
Senju et al. Pluripotent stem cell-derived dendritic cells for immunotherapy
Ramadan Generation of functional monocyte-derived fast dendritic cells suitable for clinical application in the absence of interleukin-6